Research governance framework for health and social care. by unknown
1 
Preface  
 
This Research Governance Framework for Health and Social Care takes 
account of a number of developments that have taken place since the 
framework was issued for consultation in 2002.   
 
Regulations on clinical trials involving medicines took effect in 2004.  The 
regulations clarify specific legal duties of sponsors, investigators and others in 
such trials.  The change in the law stimulated wide debate on good practice 
and regulatory process in collaborative trials.  The lessons drawn are visible 
throughout this edition and recognise the need to achieve a proper balance by 
safeguarding the rights of patients involved in clinical trials while avoiding a 
disproportionate impact on those who carry them out.   
 
There are also revisions to take account of changes in the organisation of 
research ethics committees and changes in the responsibilities for funders 
and sponsors.  Regulations affecting the use of human tissue in research took 
effect in 2006 and these have again been reflected where relevant. 
 
We hope that these changes combined with further clarification of a number of 
details will provide a solid base on which to move forward, encouraging 
greater public confidence in research and further investment and activity. 
 
 
 
 
 
Research & Development Office 
December 2006 
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BOX A: RESEARCH GOVERNANCE 
 
 Sets out principles, requirements and standards 
 Defines mechanisms to deliver them 
 Describes monitoring and assessment arrangements 
 
 Improves research and safeguards the public by: 
- enhancing ethical and scientific quality 
- promoting good practice 
- reducing adverse incidents and ensuring lessons are 
learned 
- forestalling poor performance and misconduct 
 
 Is for all those who: 
- design protocols for research 
- participate in research 
- host research in their organisation 
- fund research proposals or infrastructure 
- manage research 
- undertake research 
 
 Is for managers and staff, in all professional groups, no matter how 
senior or junior 
 
 Is for those working in all health and social care research 
environments, including: 
- primary care 
- secondary care 
- tertiary care 
- social care 
- public health 
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Section 1 Purpose and Scope 
 
BACKGROUND 
 
1.1 The Department is committed to enhancing the contribution of research 
to health and social care, and to the partnership between services and 
science.  Research is essential to the successful promotion and 
protection of health and well-being and to modern and effective health 
and social care services.  At the same time health and social care 
research can involve an element of risk, both in terms of return on 
investment and sometimes for the safety and well-being of the research 
participants.  Proper governance of research is therefore essential to 
ensure that the public can have confidence in, and benefit from, quality 
research.  The public has a right to expect high scientific, ethical and 
financial standards, transparent decision-making processes, clear 
allocation of responsibilities and robust monitoring arrangements. 
 
A NEW FRAMEWORK 
 
1.2 This document sets out a framework for the governance of research 
conducted by or on behalf of the Health & Personal Social Services 
(HPSS).  The standards in this framework apply to all research 
undertaken in the HPSS, by, or on behalf of, the Department, or Health 
& Social Services (HSS) bodies and non-Departmental Public Bodies, 
that might have an impact on the quality of health and social care 
services.  This includes clinical and non-clinical research, research 
undertaken by HPSS staff using HPSS resources, and research 
undertaken by industry, the charities, the research councils and 
universities within the health and social care systems. In certain 
circumstances some elements of Research Governance, for example 
Research Ethics, extend to non-HPSS research activity.  
  
1.3 Health and social care organisations should have systems to ensure the 
principles and requirements of this research governance framework are 
consistently applied. Health and social care organisations have to take 
this standard into account in discharging their duty of quality under 
HPSS (Quality, Improvement and Regulation) (NI) Order 2003. 
 
1.4 The aim of this framework is to bring together general principles of good 
practice including clinical trials involving medicines. That does not mean 
it imposes the same procedures on all research when the interests of 
participants and the research methods do not call for them. The 
checklists of responsibilities in Section 3 are there to help everyone 
reach agreement on arrangements that are proportionate to risk, and in 
line with good clinical practice. The framework is also offered as a 
model for the governance of research in areas outside the direct 
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responsibility of the Minister for Health where poor practice could have 
a direct impact on the health or wellbeing of the public. 
 
1.5 The framework is of direct relevance to all those who host, conduct, 
participate in, fund and manage health and social care research.  It is 
not restricted to Chief Investigators, managers or to any one 
professional group.  All service and academic staff, no matter how 
senior or junior, have a role to play in the proper conduct of research.  It 
embraces participants in research and the public in general who can 
also help to ensure that standards are understood and met. 
 
1.6 This framework seeks to promote improvements in research quality 
across the board.  As with clinical and social care governance, research 
governance aims to bring general performance up to the standard of 
those at the leading edge.  The framework provides a context for the 
encouragement of creative and innovative research and for the effective 
transfer of learning, technology and best practice to improve care. 
 
1.7 The framework also aims to prevent poor performance, adverse 
incidents, research misconduct and fraud, and to ensure that lessons 
are learned and shared when poor practice is identified.  Achievement 
of these aims will promote good practice, enhance the ethical and 
scientific quality of research and safeguard the public. 
 
DEFINITION OF RESEARCH 
 
1.8 Health and social care services generate and draw upon a wide range 
of innovative work and ideas from professionals, organisations and the 
public.  Services must promote innovation and its benefits whilst 
protecting participants from risk and waste.  Innovation embraces a 
much wider range of activities than those managed formally as 
research.  Research has a wide variety of definitions often depending 
on the circumstances under which it is used. 
 
For the purposes of this document, research is defined as a systematic 
activity that: 
 attempts to answer a clearly defined question 
 employs systematic and rigorous methods – including 
quantitative and/or qualitative paradigms 
 leads to generalisable and new knowledge 
 
 For an activity to be classified as research it must meet all three 
qualifying statements.1  (Guidance on distinguishing between Research 
and Audit is provided in Box B on page 8.) 
                                                 
1 Recent work carried out by the Central Office for Research Ethics Committees Consultation E-Group has developed a table to 
www.corec.org.uk/recs/guidance/docs/Audit_or_Research_table.pdf 
Additional guidance has been collated by the NHS Research & Development Forum and is available at the following link:
help distinguish between research, clinical audit and service evaluation.  This can be accessed at: 
www.rdforum.nhs.uk/docs/categorising_projects_guidance.doc
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ACCOUNTABILITY AND STANDARDS 
 
1.9 The guidance on clinical and social care governance sets the 
framework for putting in place systems for assuring the quality of 
innovative work in non-research contexts.  This document complements 
that work and sets out the responsibilities and standards that must be 
applied to work managed within the formal research context.  
 
1.10 This research governance framework describes: 
 arrangements to define and communicate clear quality 
standards 
 delivery mechanisms to ensure that these standards are met 
 arrangements to monitor quality and assess adherence to 
defined standards 
 
1.11 Research management processes that support this research 
governance framework should be put in place in all HPSS 
organisations, with appropriate reporting arrangements at board level. 
 
1.12 Experience from adverse incidents relating to research underlines the 
need for clearly delineated responsibilities and accountabilities for 
health and social care research.  This is of particular importance given 
the very wide range of individuals and organisations that can be 
involved in a single research project.  This includes the need for 
accountability arrangements, which in the case of human organs and 
tissue are the subject of codes of practice issued by the Human Tissue 
Authority.  The framework set out in this document therefore pays 
particular attention to clarifying responsibilities and accountabilities for 
those involved in research.  
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BOX B: RESEARCH OR AUDIT? 
 
Audit and Research have much in common; they share a rigorous approach to methodology in terms 
of design, procedure, analysis and interpretation of data.  At times, the distinction between Research 
and Audit can be blurred.  However there are a number of major differences and this table is 
provided to assist in determining what is research (and falls within this Framework) and what is audit.  
Ultimately the decision into what category a particular project belongs will fall to either an Audit 
Department or a Research Ethics Committee. 
 
In general: 
 
 Research asks the question "What ought we be doing?" while Audit asks the questions "Are we 
doing what we ought to?"  Or put another way, Research is concerned with discovering the right 
thing to do; audit is ensuring that it is done right. 
 
Further differences include: 
 
Research Audit 
 
 Research is a systematic investigation which 
aims to increase the sum of knowledge.  It 
usually involves the testing of a hypothesis or 
theory 
 Audit is a systematic approach to peer 
review of clinical or social care in order to 
identify possible improvements and to 
provide a mechanism for bringing them 
about 
 Research generates the knowledge that may 
be tested in Audit 
 Audit raises questions that might be 
answered by further research 
 Research is the act of finding the correct thing 
to do and identifying the most effective form 
of intervention.  This defines best practice 
 Audit is a test of whether things are being 
done as they should.  It compares current 
practice with current standards 
 May involve allocating service users to 
different groups for trials and analysis 
 Where service users or other service users 
are involved, they are treated alike during 
Audit investigations 
 May involve the use of a placebo (however it 
may be defined) 
 Where users are directly involved, there is 
no placebo concept 
 Research may involve a completely new 
treatment and usually investigates an area 
where there is no knowledge of the best 
practice 
 Audit does not consider a completely new 
treatment, but tests the adherence to a 
treatment that is considered to be best 
practice 
 Research results can be generalised across a 
wide population 
 Audit results are "local" to the test 
population/location/time 
 Research requires the co-operation of users 
and professionals to establish a 
representative sample so that the results of 
the research can be generalised 
 Audit requires the voluntary participation of 
specialities and departments.  The data 
recorded and analysed relate only to that 
area 
 Research results are published universally in 
order to share the knowledge with a wide 
user base of professionals 
 Audit investigations are published, usually 
at local level, to educate and publicise how 
to achieve best practice 
 Research has a defined end-point  Audit is a continuous and ongoing process 
which includes a follow-up investigation 
after a period of time 
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WHO IS AFFECTED? 
 
1.13 Listed below are some of the individuals and organisations involved in 
health and social care research: 
 service users, their relatives and organisations representing them 
 the public 
 research workers 
 universities 
 students and their supervisors 
 research ethics committees 
 research charities 
 research councils 
 health and social care professionals and professional 
organisations 
 HSS care organisations 
 voluntary and not-for-profit organisations 
 the pharmaceutical and other industries 
 the Department 
 the R&D Office 
 
 
CONCLUSION 
 
1.14 Achieving high quality in research depends on co-operation between all 
those involved.  Figure 1 (on page 10) illustrates how the Department 
will continue to work with service users and professionals, the public 
and its research partners to develop and implement this research 
governance framework to assure quality in health and social care 
research. 
 
1.15 Following the model in Figure 1 the remainder of this document is 
structured as follows: 
 
 Section 2 sets out standards 
 Section 3 details responsibilities 
 Section 4 outlines delivery and monitoring systems 
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Section 2 Standards 
 
INTRODUCTION 
 
2.1 Clinical and social care governance aims to improve the overall 
standards of clinical and social care in the HPSS and to reduce 
unacceptable variations in clinical and social care practice. Under the 
HPSS (Quality, Improvement and Regulation) (NI) Order 2003, there is 
a statutory duty of quality in place in the HPSS. This sets accountability 
at a local level for the delivery of services and for continuous 
improvement in quality. 
 
2.2 The Department is developing a range of standards to support the 
HPSS in implementing the statutory duty of quality.  These include: 
 controls assurance standards which will assist HPSS 
organisations in managing their businesses, meeting their 
objectives and protecting against risk 
 care standards for an extended range of regulated services which 
will help ensure greater consistency in the quality of services 
provided across Northern Ireland 
 high-level Quality Standards for Health & Social Care that will 
integrate key elements of quality and safety 
 
2.3 This activity is being led by the Department’s Planning and Performance 
Management Directorate and comes within the remit of the Directorate’s 
Standards and Guidelines Unit established to provide a single focus 
within the Department for the development and dissemination of 
standards and guidelines to the HPSS.  The Unit has also established 
links with national standards and best practice bodies, and is 
developing mechanisms for the systematic handling of this guidance in 
the context of the HPSS.   
 
2.4 The HPSS Regulation Quality and Improvement Authority (RQIA) has 
responsibility for monitoring and inspecting the availability and quality of 
health and social care services in Northern Ireland and for encouraging 
improvements. The Authority has responsibility for approving and 
granting registration in relation to a range of services such as nursing 
homes and residential care.  The new standards will assist the new 
Authority in its work by providing a platform for assessing, and reporting 
on, the quality of care commissioned or provided by HPSS 
organisations and independent providers.   
 
2.5 Health and social care research is not the province of a single 
discipline, profession or organisation and it is difficult for a single 
document to adequately capture the full range of legislation, standards 
and guidelines that need to be applied across this wide ranging body of 
work.  They are presented within the framework document in five 
domains: 
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 Ethics 
 Science 
 Information 
 Health, Safety and Employment 
 Finance and Intellectual Property 
 
ETHICS 
 
2.6 The dignity, rights, safety and well-being of participants must be the 
primary consideration in any research study.  Box D (page 19) 
describes a scenario to illustrate good practice in protecting research 
participants’ rights within a study. 
 
2.7 The Department requires that all health and social care research 
involving service users, care professionals or volunteers, or their 
organs, tissue or data, is reviewed independently to ensure it meets 
ethical standards2. 
 
2.8 Informed consent is at the heart of ethical research.  All studies must 
have appropriate arrangements for obtaining consent and the ethics 
review process must pay particular attention to those arrangements.  
The Department issued guidance on Consent to Examination, 
Treatment or Care in 2003.  This guidance outlines principles to be 
adhered to in obtaining informed consent, which would also apply to 
obtaining consent for research.  
 
2.9 When research involves tissue or organs it must comply with the 
provisions of the Human Tissue Act 2004, which came into effect in 
2006. For the use of tissue from patients, the consent of the patient is 
required except in the circumstances specified in the Act, such as when 
a research ethics committee has agreed to the study and the samples 
are anonymised. For the use of tissue taken post mortem, the consent 
of the person concerned before they died, or of the relatives of the 
deceased, must always be obtained. Agreeing to such research 
involves relatives in difficult choices. Arrangements must be described 
for the respectful disposal of material once the research is completed, 
and for the reporting of the findings of the research to relatives, if they 
wish it. The new Human Tissue Authority is responsible for regulating 
and giving guidance on the storage and use of human tissue and 
organs.  
 
2.10 The appropriate use and protection of service user data is also 
paramount.  All those involved in research must be aware of their legal 
and ethical duties in this respect.  Particular attention must be given to 
systems for ensuring confidentiality of personal information and to the 
security of these systems. The Department has produced “The 
                                                 
2
 Under the Medicines for Human Use (Clinical Trials) Regulations 2004, it is against the law to start or conduct a clinical trial or 
to recruit participants to a clinical trial involving a medicine until there is a favourable opinion from an ethics committee and 
authorisation from the licensing authority. 
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Protection and Use of Patient and Client Information – Guidance for the 
HPSS” available on the Department’s Website at 
http://www.dhsspsni.gov.uk/the_protection_and_use_of_patient_and_cli
ent_information.pdf.  Particular attention should be paid to paragraph 
4.21 of the guidance which emphasizes the need to advise service 
users about the planned use of their personal information. 
 
2.11 Participants or their representatives should be involved wherever 
possible in the design, conduct, analysis and reporting of research.  
Active patient and public involvement is needed to encourage research 
which benefits and reflects the needs and views of patients and the 
public. 
 
2.12 Research and those pursuing it should respect the diversity of human 
culture and conditions and take full account of equality issues such as 
religion, ethnicity, gender, disability, age and sexual orientation in its 
design, undertaking, and reporting.  Researchers should take account 
of the multi-cultural nature of society.  It is particularly important that the 
body of research evidence available to policy makers reflects the 
diversity of the population. 
 
2.13 Some research may involve an element of risk to those participating in 
it. If there are any risks to participants, the risks must be in proportion to 
the potential benefit3 .  Risks, pain or discomfort must always be kept to 
a minimum and explained clearly to the relevant ethics committee and 
to participants.  Arrangements for compensation in the unlikely event of 
non-negligent harm must always be explained. 
 
2.14 Some essential research into important illnesses and treatments can 
only be conducted with animals.  When considering undertaking 
research which could involve the use of animals, alternatives such as 
cells, tissues, bacteria, plants and computer models must be considered 
and used wherever possible.  Where animal use is unavoidable, there 
are strict statutory controls, enforced under the Animals (Scientific 
Procedures) Act 1986.  Before a researcher can use animals, specific 
project and personal licences must be obtained from the Department; 
primates are only to be used if less advanced animals could not provide 
the information; researchers must have the necessary skills, training 
and experience, and the research laboratory must have the facilities to 
care for the animals properly.  In addition, there are three principles (the 
3 Rs) that should be followed: replacement of animals by non-animal 
methods wherever possible; reduction of numbers to the minimum 
necessary to obtain valid results where replacement is not possible; and 
refinement of all procedures to minimise adverse effects.  The highest 
standards of animal husbandry and welfare under veterinary 
supervision must be maintained at all times and an ethical review 
                                                 
3 Unless the risk to them is negligible, it is unethical to involve adults without capacity to consent, or minors, in research that 
could have no therapeutic benefit for the group involved. 
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process must operate in accordance with the Departmental 
requirements.   
 
SCIENCE 
 
2.15 It is essential that existing sources of evidence, especially systematic 
reviews, are considered carefully prior to undertaking health and social 
care research.  Research which duplicates other work unnecessarily or 
which is not of sufficient quality to contribute something useful to 
existing knowledge is in itself unethical. 
 
2.16 All proposals for health and social care research must be subjected to 
review by experts in the relevant fields able to offer independent advice 
on its quality which is independent of the researcher.  Arrangements for 
peer review must be commensurate with the scale of the research.  For 
example, in the case of student research projects the university may 
provide an adequate level of review. 
 
2.17 The Medicines for Human Use (Clinical Trials) Regulations 20044 
regulate trials of medicines on people. Authorisation by the Medicines 
and Healthcare products Regulatory Agency (MHRA) is required. The 
Agency offers advice and undertakes inspections for such trials – and 
the manufacture and assembly of products used in them – against 
international standards. The same Agency regulates research involving 
new medical devices. The principles of Good Clinical Practice apply to 
all research involving patients, not just clinical trials5.  
 
2.18 Special regulations govern the use of human embryos, the release of 
genetically modified organisms and food or food processes.   
 
2.19 Data collected in the course of research must be retained for an 
appropriate period to allow further analysis by the original or other 
research teams subject to consent and to support monitoring of good 
research practice by regulatory and other authorities.   
                                                 
4
 The Medicines for Human Use (Clinical Trials) Regulations 2004 transposed Directive 2001/20/EC into UK law. 
5
 The Medical Research Council issued guidelines in 1998 for Good Clinical Practice in clinical trials in the public and charity 
sectors.  The MRC guidelines apply the principles of Good Clinical Practice in the 1996 statement of the International 
Conference on Harmonisation (ICH GCP). 
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BOX C:  PROTECTING RESEARCH PARTICIPANTS’ RIGHTS 
 
 
What does it really feel like to be asked to participate? 
 
The scenario:  A Professor of Social Work was awarded a grant by the R&D Office to study support 
services for adoptive families.  The research involved the study of adopted children and their parents.  
The study included children aged between 8 and 14. 
 
The study involved a survey of, and interviews with, a sample of adoptive parents.  The research 
team sent the adoptive parents a letter and standard information sheet about the children’s study.  
The information provided aimed to help them come to a decision about whether to support their 
child’s participation in the research.  It covered the project aims, interview arrangements, interview 
topics, and consent and confidentiality.  It invited them to discuss over the phone any aspect of the 
study with the research team. 
 
Enclosed with the parents’ letter and information sheet was an information pack for them to pass on 
to their child.  The letter noted that the child might be puzzled by its arrival, and suggested that it 
might be helpful for them to explain that they have already taken part in the project.  Before handing 
the pack to their adopted child, the parents had some questions about the study that the mother put 
to the lead researcher over the phone.  The researcher clarified that the mother was speaking for 
herself and the child’s adoptive father. 
 
Parent – I've read the information, I think I understand it, but there are a few points I'm not 
sure about.  I think my daughter may be keen to take part, but I'm worried she might find it 
upsetting. 
 
Researcher – I can't really say that there's no possibility of something coming up that she may find 
upsetting.  But if your daughter finds a question upsetting she won't have to answer it and she can 
stop the interview at any time.  At the start of the interview we'll help her to rehearse telling us that 
she doesn't want to answer particular questions or that she doesn't want to go on.  In the Information 
Sheet we noted down some of the topics we want to cover.  Is there anything about your daughter's 
experience that it might be particularly helpful for the interviewer to be aware of? 
 
Parent – No, I can't think of anything…, but will you tell me what she says? 
 
Researcher – No, we'll reassure her that whatever she says won't be repeated to you, her teachers, 
or anyone else she knows.  But we'll also let her know that she can tell other people about the 
interview if she wants to.  If she talks about any problems which it seems you or other people aren't 
aware of, we'll explore whether she wants to talk about them with anybody else and, if appropriate, 
we'll gently encourage her to do so.  In our other research with children, we've found that once 
they've talked about a problem during an interview they're usually quite keen to talk about it with 
someone else. 
 
Parent – How do I know it'll be worthwhile? 
 
Researcher – At present we know very little about children's view of adoption.  We particularly need 
to know if support services need to be improved for adopted children and their families.  The study 
has been commissioned by the Department and the findings will be fed directly into the Department's 
review of adoption.  A panel of experts have checked the scientific design and it has undergone an 
ethical review. 
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BOX C: CONTINUED 
 
Parent – If she says 'yes' can she pull out later? 
 
Researcher – Yes.  She can change her mind whenever she wants.  We have put that in writing for 
you and your daughter. 
 
Parent – When the study's finished will you tell us what you've found out? 
 
Researcher – Yes, there will be a summary of our findings especially written for all the families 
who've taken part. 
 
Parent – Do I have to make my mind up now? 
 
Researcher – No, we don't need to know today, but it would be helpful if we knew by the 20th of next 
month – that's about four weeks away.  Think about it for a while and call me again if you have any 
more questions. 
 
Scenario:  A week or so later the parent decided to pass on the information pack about the study to 
her eight-year old daughter.   This introduced the research team and explained that they were writing 
a book about adoption.  It also explained the purpose and scope of the interview, and arrangements 
for gaining their consent and protecting their confidentiality.  A few days later the child rang with her 
own questions: 
 
Child – How long do you want to talk to me? 
 
Researcher – For about an hour, but if you've only a few things to say it could be less than an hour.  
If you have a lot to say it could take longer. 
 
Child – Will you tell anyone what I say? 
 
Researcher – No one outside the research team will know your name.  People will read about the 
things you say to us, but they will not know who said those things.  You can choose whether YOU tell 
anyone else.  The only thing is, we do have to report it if you say someone has broken the law. 
 
Child – Will you write down what I say? 
 
Researcher – Maybe, but we'd really like to tape what you say if that's OK with you. 
 
Child – Will anybody reading the book know me? 
 
Researcher – No one will know your name except us. 
 
Child – Will you all come to speak to me? 
 
Researcher – No, just one of us. 
 
Child – Can I change my mind? 
 
Researcher – Yes, of course.  You can change it at any time. 
 
Child – What if I'm not sure? 
 
Researcher – Take your time.  We don't need to know straightaway.  Talk to someone else about it if 
that helps, but it would be helpful if you could let me know in about three weeks time.  If I have not 
heard from you by 20th, I will take it that you've decided that you don't want to take part.  If you do 
decide to take part, you can change your mind at any time. 
 
This researcher is trying to do the right things in the right way.  The principles of the research 
governance framework are reflected in her practice. 
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2.4 INFORMATION 
 
2.20 Health and social care research is conducted for the benefit of service 
users, care professionals, and the public in general.  There should be 
free access to information both on the research being conducted and on 
the findings of the research, once these have been subjected to 
appropriate scientific review.  This information must be presented in a 
format understandable to the public.  Reports need to be 
comprehensible and take language and other needs into account.  
 
2.21 Some advances in health and social care need to be developed 
commercially if they are to be made widely available.  Drugs, medical 
devices and aids for disabled people are examples.  Successful 
commercial development often depends upon the effective protection of 
intellectual property or commercial confidentiality at critical points in the 
innovation process6.  The timing of the publication of research findings 
needs to take account of this. 
 
2.22 All those conducting health and social care research should aim to 
ensure that their findings are available to others through appropriate 
dissemination.  This will usually entail publishing their work.  Research 
findings must be subjected to critical review through the accepted 
scientific and professional channels.  Where studies involve direct 
contact with service users (including the relatives of deceased users 
who have consented to the use of organs or tissue in the research), or 
the public, researchers should provide accessible accounts of the 
research and, when completed, of its findings to those involved, 
including to the study participants7. 
 
HEALTH, SAFETY AND EMPLOYMENT 
 
2.23 Health and social care research may involve the use of potentially 
dangerous or harmful equipment, substances or organisms.  The safety 
of participants, and of research and other staff must be given priority at 
all times, and health and safety regulations must be strictly observed. 
 
FINANCE AND INTELLECTUAL PROPERTY 
 
2.24 Financial probity and compliance with the law and with the rules laid 
down by Department of Finance and Personnel and HM Treasury for 
the use of public funds are as important in research as in any other 
area. 
 
2.25 Organisations employing researchers must be in a position to 
compensate anyone harmed as a result of their negligence.  Any 
                                                 
6 Researchers are advised to consult the HPSS Innovations Advisor at the Clinical Research Support Centre. 
7 There is an international consensus that, with certain exceptions, information identifying a clinical trial of a treatment should 
be available on a public register from the time the first participant is recruited. 
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organisation offering participants compensation in the event of non-
negligent harm must be in a position to do so. 
 
2.26 Careful consideration must be given to the appropriate exploitation of 
intellectual property rights.   
 
QUALITY RESEARCH CULTURE 
 
2.27 Some of the principles and requirements applying to health and social 
care research are clear-cut but many require judgement and 
interpretation.  A quality research culture, where excellence is promoted 
and where there is visible and strong research leadership and expert 
management, is essential if researchers and managers are to 
understand and apply standards correctly.  A quality research culture is 
thus essential for proper governance of health and social care research. 
 
2.28 The key elements of a quality research culture are: 
 
 respect for participants’ dignity, rights, safety and well-being 
 valuing the diversity within society 
 personal and scientific integrity 
 leadership 
 honesty 
 accountability 
 openness 
 clear and supportive management 
 
2.29 Box D (page 19 and 20) illustrates how research is managed in a HSS 
body with a quality research culture. 
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BOX D:  STANDARDS IN A QUALITY ORGANISATION 
UNDERTAKING RESEARCH 
 
Quality Research Culture 
  The organisation supports and promotes high quality research as part of a service culture 
receptive to the development and implementation of best practice in the delivery of care.  
There is strong leadership of research and a clear strategy linking research to 
Departmental priorities and needs, the organisation’s business, to clinical and social care 
governance (in HPSS organisations) and the delivery of best value.   
 The organisation’s research strategy values diversity in its service users and its staff and 
promotes their active participation in the development, undertaking and use of research.   
 The organisation promotes a culture that is sensitive to the needs of more vulnerable 
groups that are involved in research. 
 
 
Ethics 
  All research which involves patients, service users or care professionals and other staff or 
their organs, tissue or data is referred to independent ethical review to safeguard their 
dignity, rights, safety and well-being. 
 Consent is sought in the way agreed during ethical review. 
 Research is pursued with the active involvement of service users and carers including, 
where appropriate, those from hard to reach groups such as homeless people. 
 If organs or tissue are used following post mortems, informed consent is obtained from 
relatives, and there is a commitment to respectful disposal of material. 
 If animal use is unavoidable the highest standards of animal husbandry are maintained 
under veterinary supervision. 
 
 
Science 
  There is commitment to the principles and practice of scientific review by independent 
experts, with scrutiny of the suitability of protocols and research teams for all work in the 
organisation. 
 There is close collaboration with partner organisations in higher education, research and 
care to ensure quality and relevance of joint work and avoidance of unnecessary 
duplication of functions. 
 Systems are in place to monitor compliance with standards and to investigate complaints 
and deal with irregular or inappropriate behaviour in the conduct of research. 
 The organisation assesses its research outputs and their impact and value for money. 
 
 
Health, Safety & Employment 
  The organisation’s human resource strategy included commitment to support research 
careers (full and part-time) by earmarking funds specifically for R&D training across the 
professions.  The organisation plays its role in developing research capacity with 
appropriate training and updating.  This includes taking action to ensure that the diversity 
of the workforce reflects society and developing the capacity of consumers to participate. 
 The organisation promotes a high standard of health and safety in office, laboratory and 
field work. It follows Good Laboratory Practice, Good Manufacturing Practice in 
manufacturing products for clinical trials and Good Clinical Practice in conducting clinical 
trials. 
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BOX D:  (Continued) 
 
Information 
  Information is available on all research being undertaken in the organisation.  It is held on 
a database, containing details of research providers, funding, intellectual property rights, 
recruitment, research outputs and impact. 
 The organisation ensures that patients, service users, carers, health and social care 
professionals and other staff have easy access to information on research.  Where 
necessary special arrangements are made to ensure access to information for those who 
do not have English as a first language, cannot read or may need information in different 
formats because of a disability eg Braille. 
 An information service provides access from a single point to all up-to-date regulatory and 
advisory documentation pertaining to research governance, together with procedural 
guidance, for example, for applications to research ethics committees. 
 When established, findings (including negative findings) are published in ways that allow 
critical review and dissemination to those who could benefit from them.  Other researchers 
have access to the data on which the findings are based. 
 There is a strategy for making research findings accessible.  It addresses different media 
and writing styles for different audiences.  Unless the research ethics committee agrees 
otherwise, those consenting to be involved in a study (including the relatives of deceased 
patients who have consented to the use of organs or tissue in the research) have ready 
access to the findings at the end of the study. 
 
 
 
Finance 
  The organisation is aware of the activity involved in supporting research and of what it 
costs.  Research expenditure is planned and accounted for. 
 The organisation demonstrates financial probity and compliance with the law and rules laid 
down by the Department of Finance and Personnel.  It complies with all audit required by 
external funders or sponsors and has systems in place to deter, detect and deal with fraud. 
 The organisation has in place indemnity arrangements as part of their system of 
safeguards. 
 When research findings have commercial potential the organisation takes action to protect 
and exploit them, in collaboration with its research partners and – when appropriate – 
commercial organisations. 
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Section 3 Responsibilities and Accountability 
 
GENERAL 
 
3.1 All those involved in research with human participants, their organs, 
tissues or data must be aware of and implement the law and the basic 
principles relating to ethics, science, information, health and safety, and 
finance set out in this framework. 
 
3.2 All those involved in research also have a duty to ensure that they and 
those they manage are appropriately qualified, both by education and 
experience, for the role they play in relation to any research.  They must 
be aware of, and have ready access to, sources of information and 
support in undertaking that role. 
 
AGREEMENTS 
 
3.3 A complex array of organisations and individuals may be involved in a 
health or social care research study.  It is essential that clear 
agreements describing allocation of responsibilities and rights for a 
study are developed, documented and enacted. 
 
3.4 While many agreements relate to individual studies, organisations that 
collaborate on a range of research work may find it helpful to develop 
and document framework agreements to facilitate the agreement of 
responsibilities for specific studies.  Examples of collaborations where 
framework agreements are necessary include: 
 
 HSS bodies (eg Trusts, special agencies, HSS Boards and the 
new HSS Authority) who work together regularly on research, 
whether or not in a formal network 
 universities and HSS bodies that work together regularly on 
research 
 
3.5 It is particularly important that clear and documented agreements are in 
place for complex studies where there may be: 
 
 work on more than one site 
 researchers employed by more than one organisation 
 users and professionals from more than one organisation; 
and/or more than one funder 
 
3.6 The NHS/HPSS R&D Partnership with the Pharmaceutical Industry 
launched in 2003 sets out principles for industry involvement in 
commercial contract research and in collaborative studies. A model 
Clinical Trial Contract (mCTA), revised in 2006, is intended for use in 
those clinical trials, sponsored by pharmaceutical and biotech 
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companies, which involve HPSS service users.  The mCTA is designed 
to speed up the initiation of trials whilst providing the assurance that 
appropriate arrangements are in place to protect service users and the 
organisations responsible for their care.  A Northern Ireland specific 
version of the mCTA is available and is endorsed for routine use without 
amendment by the Department, the Association of the British 
Pharmaceutical Industry, the Bio Industries Association, the Council of 
Heads of Medical Schools, the UK Clinical Research Collaboration and 
the NHS R&D Forum.  For contract clinical trials in secondary care, 
clinical trial agreements will be between the commercial sponsor and 
each HSS body accountable for the care of HPSS patients participating 
in the trial. In primary care, these contracts will normally be between the 
commercial sponsor and General Practitioners or Practices. For 
collaborative studies with a contribution from industry, the commercial 
partner’s contract may be with a university or HSS body depending on 
the circumstances.   
 
SPECIFIC RESPONSIBILITIES 
 
3.7 Box E (page 23-24) describes the people and organisations that may be 
involved in a health and social care research study.  The key 
responsibilities of the people and organisations accountable for the 
proper conduct of a study are summarised in Box F (page 28-29). 
 
3.8 The remainder of this section sets out these responsibilities in more 
detail.  Box G (page 38 - 40) illustrates these responsibilities by way of 
a scenario. 
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BOX E: 
MAIN PEOPLE AND ORGANISATIONS 
INVOLVED IN A HEALTH OR SOCIAL CARE 
RESEARCH STUDY 

Participant 
Patient, service user, carer, relative of the deceased, professional carer, other employee, or member 
of the public, who consents to take part in a study. (In law, participants in clinical trials involving 
medicines are known as subjects.) 
 
Chief Investigator8 
The person who takes overall responsibility for the design, conduct and reporting of a study if it is at 
one site; or if the study involves researchers at more than one site, the person who takes primary 
responsibility for the design, conduct and reporting of the study, whether or not that person is an 
investigator at any particular site.  For clinical trials involving medicines, the Chief Investigator must 
be an authorised health professional. 
 
Principal Investigator8 
Person responsible for the conduct of the clinical trial at an individual trial site.  If a trial is conducted 
by a team of individuals at a trial site, the investigator leading the team is called the Principal 
Investigator.  For clinical trials involving medicines, the Principal Investigator must be an authorised 
health professional. 
 
Researchers/Investigators 
Members of the research team other than the Chief Investigator or the Principal Investigator.  For 
clinical trials involving medicines, an investigator must be an authorised health professional. 
 
Funder 
Organisation providing funding for a study (through contracts, grants or donations to an authorised 
member of the employing and/or care organisation). The main funder typically has a key role in 
scientific quality assurance. In any case, it remains responsible for securing value for money. 
 
Sponsor 
Individual, organisation or group taking on responsibility for securing the arrangements to initiate, 
manage and finance a study. (A group of individuals and/or organisations may take on sponsorship 
responsibilities and distribute them by agreement among the members of the group, provided that, 
collectively, they make arrangements to allocate all the responsibilities in this research governance 
framework that are relevant to the study.) 
 
 
                                                 
8 The terms Chief Investigator (CI), Principal Investigator and Investigator (PI) are used in different contexts with a variety of 
regulatory/legislative origins.  All research studies must be led by a CI irrespective of the number of sites/centres involved.  
There can only be one CI for any given study.  The role of CI cannot be split between more than one person.  The term PI only 
becomes relevant where a research study involves more than one site/centre.  In those sites/centres other than the co-
ordinating site/centre the lead researcher is referred to as the PI.  The PI may be the sole investigator at a site/centre or lead a 
team of investigators. 
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BOX E: (continued) 
 
Employing organisation 
Organisation employing the Chief Investigator, Investigators or other researchers. Employers remain 
liable for the work of their employees. The organisation employing the Chief Investigator normally 
holds the contract or grant agreement with the funder of the study. Organisations holding contracts 
with funders remain responsible for the management of the funds provided. 
 
Organisation providing care 
Organisation responsible for providing health and/or social care to patients and/or service users and 
carers participating in a study. Health and social care organisations remain liable for the quality of 
care, and for their duty towards anyone who might be harmed by a study. 
 
Responsible care professional 
Doctor, nurse, social worker or other practitioner formally responsible for the care of participants while 
they are taking part in the study. 
 
Research ethics committee 
Committee established to provide participants, researchers, funders, sponsors, employers, care 
organisations and professionals with an independent opinion on the extent to which proposals for a 
study comply with recognised ethical standards. For clinical trials involving medicines, the ethics 
committee must be one recognised by the United Kingdom Ethics Committees Authority. 
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RESPONSIBILITIES OF PARTICIPANTS 
 
3.9 Improvements in effective and responsive services depend upon 
research.  Through this framework and related provisions, the 
Department and its research partners will strive to ensure that research 
conducted in health and social care offers the likelihood of real benefits 
either to those who participate, or those who use services subsequently, 
or both.  All those using the HPSS should give serious consideration to 
invitations to become involved in the development or undertaking of 
research studies. 
 
3.10 Researchers must develop means of communication that ensure 
potential participants are fully informed before deciding whether or not 
to join a study. In clinical trials involving medicines, there is a legal 
requirement to provide an interview with a member of the research team 
and a contact point offering further information about the trial. Potential 
participants should not hesitate to ask if they do not understand the 
information and explanations given.  
 
RESPONSIBILITIES OF RESEARCHERS 
 
3.11 Researchers bear the day-to-day responsibility for the conduct of 
research. They are responsible for: 
 ensuring that any research they undertake follows the current 
version of the agreed study protocol 
 helping care professionals to ensure that participants receive 
appropriate care while involved in research 
 reporting any adverse drug reactions or other adverse events 
 protecting the integrity and confidentiality of clinical and other 
records and data generated by the research 
 reporting any failures in these respects, or suspected 
misconduct, through the appropriate systems 
 
RESPONSIBILITIES OF THE CHIEF INVESTIGATOR 
 
3.12 A senior individual must be designated as the Chief Investigator for any 
research undertaken in or through the HPSS, which involves 
participants or their organs, tissue or data. There can be only one Chief 
Investigator and this role cannot be split between one or more 
individuals.  The Chief Investigator normally takes responsibility for the 
conduct of the research at a site, and is accountable for it to their 
employer, and through them to the sponsor of the research. The Chief 
Investigator is also directly accountable to the care organisation(s) 
where the research takes place (or through which the research team 
has access to participants, their organs, tissue or data). If the research 
is at more than one site, the Chief Investigator takes on personal 
responsibility for the design, management and reporting of the study, 
and co-ordinating the investigators who take the lead at each site. 
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3.13 Chief Investigators must have suitable experience and expertise in the 
design and conduct of research9 so that they are able either to: 
study to the standards set out in this framework; or 
 lead and manage others with delegated responsibility for some of 
these aspects 
 
3.14 For health and social care research, the Chief Investigator is 
responsible for ensuring the following: 
 the research team gives priority at all times to the dignity, rights, 
safety and wellbeing of participants 
 the research study complies with all legal and ethical 
requirements 
 the research is carried out to the standards in this research 
governance framework 
 trials involving human participants must be registered, and for 
clinical trials involving medicines, the research follows any 
conditions imposed by the licensing authority 
 the Chief Executive of the care organisation(s) involved and/or 
any other individual(s) with responsibilities within this framework 
are informed that the study is proposed, and their permission is 
obtained before the research starts 
 when a study involves participants under the care of a doctor, 
nurse or social worker for the condition to which the study relates, 
those care professionals are informed that their patients or users 
are being invited to participate, and agree to retain overall 
responsibility for their care 
 when the research involves a service user or carer or a child, 
looked after or receiving services under the auspices of an HSS 
Trust, the appropriate director or deputy agrees to the person 
(and/or their carer) being invited to participate, and is fully aware 
of the arrangements for dealing with any disclosures or other 
relevant information 
 potential participants and other service users and carers are 
involved in the design and management of the study whenever 
appropriate 
 the study is submitted for ethics review and it does not start 
without a favourable opinion, and the research team acts on any 
conditions attached to the ethics opinion 
 unless participants or the ethics opinion says otherwise, 
participants’ care professionals are given any information directly 
relevant to their care that arises in the research 
 each member of the research team, including those at 
collaborating sites, is qualified by education, training and 
                                                 
9 For clinical trials involving medicines, the Chief Investigator and other investigators must be authorised health professionals 
as defined in the Medicines for Human Use (Clinical Trials) Regulations 2004. 
 undertake the design, conduct analyses and reporting of the 
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experience to discharge his/her role in the study and their 
qualifications are documented 
 each investigator in a clinical trial involving medicines is aware of 
his/her legal duties 
 students and new researchers have adequate supervision, 
support and training 
 unless urgent safety measures are necessary10, the research 
follows the protocol agreed by the relevant research ethics 
committee and by the sponsor11 
 substantive changes to the protocol or proposal are submitted for 
ethical review and for the sponsor’s agreement12. These 
amendments are implemented only when approved  
 procedures are kept in place to ensure collection of high quality, 
accurate data and the integrity and confidentiality of data during 
processing and storage13 
 there are appropriate arrangements to archive the data when the 
research has finished, and to make it accessible 
 reports on the progress and outcomes of the work required by the 
sponsor, funders, or others with a legitimate interest are produced 
on time and to an acceptable standard 
 the findings from the work are opened to critical review through 
the accepted scientific and professional channels 
 once established, findings from the work are disseminated 
promptly and fed back as appropriate to participants 
 the Chief Investigator accepts a key role in detecting and 
preventing scientific misconduct by adopting the role of guarantor 
on published outputs 
 arrangements are kept in place for the management of financial 
and other resources provided for the study, including for the 
management of any intellectual property arising 
 all data and documentation associated with the study are 
available at the request of the inspection and auditing authorities 
 
 
                                                 
10 Investigators in clinical trials involving medicines have to report serious adverse events immediately. 
11 For clinical trials involving medicines, it is a legal requirement to follow the protocol approved by the licensing authority (the 
Medicines and Healthcare products Regulatory Agency). 
12 Also, for clinical trials involving medicines, to the licensing authority. 
13 Also, for clinical trials involving medicines, procedures to comply with legal requirements concerning Good Clinical Practice 
during the trial, and Good Manufacturing Practice in manufacturing investigational medicinal products.  
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BOX F: 
SUMMARY OF KEY RESPONSIBILITIES OF PEOPLE AND ORGANISATIONS 
ACCOUNTABLE FOR THE PROPER CONDUCT OF A STUDY 
 
Chief Investigator, Investigators, other Researchers 
  Developing proposals that are scientifically sound and ethical. 
 Submitting the design for independent expert review. 
 Submitting the study (or proposal) for independent ethical review. 
 Conducting a study to the agreed protocol (or proposal), in accordance with legal 
requirements, guidance and accepted standards of good practice. 
 Preparing and providing information for participants. 
 Ensuring participants’ welfare while in the study. 
 Arranging to make findings and data accessible following expert review. 
 Feeding back results of research to participants. 
 
See sections, 3.11 - 3.14 
 
 
Main Funder 
  Assessing the scientific quality of the research as proposed. 
 Establishing the value for money of the research as proposed. 
 Considering the suitability of the research environment in which the research will be 
undertaken, particularly the experience and expertise of the Chief Investigator(s) and other 
key researchers involved. 
 Requiring that a sponsor takes on responsibility before the research begins. 
 
See sections, 3.15 - 3.19 
 
 
Sponsor 
  Confirming that everything is ready for the research to begin: 
 Taking on responsibility for putting and keeping in place arrangements to initiate, 
manage and fund the study. 
 Satisfying itself the research protocol, research team and research environment 
have passed appropriate scientific quality assurance.  
 Satisfying itself the study has ethical approval before it begins; 
 For clinical trials involving medicines, seeking a clinical trial authorisation and 
making arrangements for investigational medicinal products. 
 Satisfying itself that arrangements are kept in place for good practice in conducting the 
study, and for monitoring and reporting, including prompt reporting of suspected 
unexpected serious adverse events or reactions. 
 
See section, 3.20 - 3.25 
 
 
Employing Organisation 
  Promoting a quality research culture. 
 Ensuring researchers understand and discharge their responsibilities. 
 Ensuring studies are properly designed and submitted for independent review. 
 Ensuring studies are managed, monitored and reported as agreed, according to the 
protocol. 
 Providing written procedures, training and supervision. 
 Taking action if misconduct or fraud is suspected. 
 
See section, 3.26 - 3.29 
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BOX F:  (continued) 
 
Organisation providing care/ Responsible care professional 
  Arranging for an appropriate person to give permission for research involving their 
patients, service users, carers or staff, before the research starts. 
 Ensuring any such research is conducted to the standards set out in this research 
governance framework. 
 Requiring evidence of ethical review before recruitment to any research that affects their 
duty of care. 
 Before recruitment to trials with medicines, requiring evidence of a positive ethical opinion 
and a clinical trials authorisation. 
 Retaining responsibility for the care of participants to whom they have a duty. 
 
See section, 3.30 - 3.33 
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RESPONSIBILITIES OF RESEARCH FUNDERS 
 
3.15 Organisations that fund research have a responsibility for ensuring that 
the work is a proper use of the funds they control and provides value for 
money. 
 
3.16 The main research funder plays a critical role in assuring the quality of a 
study. It will normally take the lead in establishing that the research 
proposal is worthwhile, of high scientific quality, and represents good 
value for money14. 
 
3.17 The main research funder is normally the organisation that makes 
arrangements for independent expert review to assess: 
 the quality of the research as proposed 
 the experience and expertise of the Chief Investigator and other 
key researchers 
 whether there is appropriate research infrastructure for the 
study: for example, management and governance 
arrangements; access to potential participants (or their organs, 
tissue or data); specialised facilities such as equipment, 
materials or support staff 
 for trials on medicines, expert clinical trial management and the 
capacity to comply with the principles of Good Clinical Practice 
 
If the main funder is unable to arrange for independent expert review, 
the sponsor is expected to arrange for it before taking on responsibility 
for the study, or to require another organisation to arrange for it. It is 
good practice for funders to make scientific judgements related to their 
responsibilities with expert advice independent of the investigators. 
 
3.18 Funders are expected to provide assistance to any enquiry, audit or 
investigation related to the funded work. 
 
3.19 Funders are expected to make their funding conditional on identifying a 
sponsor. Organisations wishing to fund research requiring the 
collaboration of the HPSS will either take on sponsorship themselves, or 
collaborate with another organisation that is willing and able to do so. 
Potential collaborators may be other funders, or employers of 
researchers, including health or social care providers that are ready in 
principle to sponsor studies within programmes of research funded by 
the Department or the HPSS.   
 
 
                                                 
14
 The value for money assessment compares the potential benefits with the resources that the study requires.  These 
resources include any additional care or treatment costs, as well as the research costs that the funder is to meet. 
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RESPONSIBILITIES OF RESEARCH SPONSOR 
 
3.20 The sponsor is the individual, or organisation (or group of individuals or 
organisations) that takes responsibility for confirming there are proper 
arrangements to initiate, manage and monitor, and finance a study15. 
For any research that takes place in the context of the HPSS there must 
be a sponsor. Normally, the sponsor will be one of the organisations 
taking the lead for particular aspects of the arrangements for the study. 
It may be the Chief Investigator’s employing organisation, or the lead 
organisation providing health or social care, or the main funder. If the 
sponsor is outside the United Kingdom16, it must have a legal 
representative in the United Kingdom. For any research study covered 
by this research governance framework, it is for the sponsor to be 
satisfied that clear agreements are reached, documented and carried 
out, providing for proper initiation, management, monitoring and 
financing. Others will rely on reasonable assurances that the sponsor 
has taken steps to do this. 
 
3.21 The sponsor is responsible for ensuring before a study begins that 
arrangements are in place: 
 for the research team to access resources and support to deliver 
the research as proposed 
 to allocate responsibilities for the management, monitoring and 
reporting of the research 
 
The sponsor also has to be satisfied there is agreement on appropriate 
arrangements to: 
 record, report and review significant developments as the 
research proceeds particularly those which put the safety of 
individuals at risk 
 approve any modifications to the design, obtain any regulatory 
authority required, implement them, and make them known 
 
3.22 It is the sponsor’s responsibility to be satisfied with the arrangements for 
management and monitoring. Normally, if the Chief Investigator’s 
employer takes on the sponsor’s responsibilities (alone or as a member 
of a group), it will assume responsibility for operating the management 
and monitoring systems in collaboration with the employers of other 
members of the research team. Exceptionally, it may be inappropriate 
for the Chief Investigator’s employer to take responsibility for the 
management and monitoring of a study. In that case, the sponsor 
should make arrangements with one or more other organisations that 
                                                 
15 For clinical trials involving medicines, the sponsor is defined as the person (e.g. individual, institution, company or 
organisation) who takes responsibility for the initiation, management and financing (or arranging the financing) of that trial.  
Such sponsors have specific legal duties under the Medicines for Human Use (Clinical Trials) Regulations 2004.  Regulation 3 
defines options for sponsorship, including single sponsorship, joint sponsorship and allocation of sponsorship responsibilities 
within a group. 
16 The Regulations require a sponsor to be established, or have a legal representative, in the European Community.  Neither of 
them needs to be established in the United Kingdom. 
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will operate the management and monitoring systems. 
 
3.23 Provided the sponsor keeps in place arrangements for performance 
management and audit, the responsibility for design and management 
may be delegated to the research team. The extent of delegation should 
be specified, even for a research team with proven expertise and track 
record. Commercial sponsors may arrange for their own audit 
processes. 
 
3.24 Where research has no external sponsor, care organisations may, if 
they wish the unsponsored research to proceed, accept the 
responsibility of the sponsor.  For example, an HSS Trust may be 
willing, and able, to act as the sponsor for research which does not 
have an external sponsor (sometimes called "own account" research).  
Alternatively an HSS Trust may decline the opportunity for that research 
to proceed within its care organisation. 
 
3.25 It is the sponsor’s responsibility to be satisfied that: 
 the research study respects the dignity, rights, safety and 
wellbeing of participants and the relationship with care 
professionals 
 an appropriate process of independent expert review has 
demonstrated the research study to be worthwhile, of high 
scientific quality and good value for money 
 an appropriate research ethics committee or independent ethics 
reviewer has given a favourable opinion 
 in the case of a clinical trial involving a medicine, someone acting 
on behalf of the sponsor obtains a clinical trial authorisation, and 
the arrangements for the trial comply with the law 
 appropriate arrangements are in place for the registration of a trial 
 the Chief Investigator, and other key researchers, including those 
at collaborating sites, have the necessary expertise and 
experience and have access to the resources needed to conduct 
the proposed research successfully 
 the arrangements and resources proposed will allow the 
collection of high quality, accurate data, and the systems and 
resources proposed are those required to allow appropriate data 
analysis and data protection 
 arrangements proposed for the work are consistent with this 
research governance framework 
 organisations and individuals involved in the research agree the 
division of responsibilities between them 
 there is written agreement about the arrangements for the 
management and monitoring of the study 
 arrangements are in place for the sponsor and other stakeholder 
organisations to be alerted to significant developments17 during 
                                                 
17 For clinical trials involving medicines, these include serious adverse events, serious adverse reactions, and suspected 
unexpected serious adverse effects as defined in the Medicines for Human Use (Clinical Trials) Regulations 2004. 
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the study, whether in relation to the safety of individuals or to 
scientific direction18  
 agreement has been reached about compensation in the event of 
harm to research participants19; and if any organisation, or the 
sponsor itself, offers compensation without proof of negligence, it 
has made the necessary financial arrangements 
 there are arrangements for the conclusion of the study including 
appropriate plans for disseminating the findings 
 
The sponsor is expected to assist any enquiry, audit or investigation 
related to the research. 
 
 
RESPONSIBILITIES OF ORGANISATIONS EMPLOYING RESEARCHERS 
 
3.26 Employers of staff undertaking health and social care research have 
responsibility for developing and promoting a quality research culture in 
their organisation and for ensuring that their staff are supported in, and 
held to account for, the professional conduct of research.  This will 
involve careful attention to training, career planning and development, 
and the use of clear codes of practice and systems for monitoring 
compliance, dealing with non-compliance or misconduct and learning 
from complaints.  These responsibilities apply to both private and public 
sector employers. 
 
3.27 Organisations that employ Chief Investigators and other researchers 
have responsibility for ensuring that those researchers understand and 
discharge the responsibilities set out for them in this framework, and 
under the law. They may do this, for example, through terms of 
employment, staff handbooks, and training. They will normally take on 
some or all of the responsibility for ensuring that a study is properly 
managed and for monitoring its progress. When the employing 
organisation is not the sponsor, it should agree its responsibilities with 
the sponsor and the organisation(s) providing care. The sponsor has to 
be satisfied with the arrangements for the management of a study; and 
that there is agreement on appropriate arrangements for monitoring and 
reporting20.  
 
3.28 Employers should ensure that agreements are in place between them 
and their staff and between them and research funders and care 
organisations about ownership, exploitation and income from any 
intellectual property that may arise from research conducted by their 
employees.  They have a responsibility for ensuring that employees 
identify and protect intellectual property. 
                                                 
18 For clinical trials involving medicines, the sponsor has a legal duty to record and report suspected unexpected serious 
adverse reactions as soon as possible.  The sponsor also has to provide annually a list of all such reactions occurring in the 
past year, and a report on the safety of the participants in the trial. 
19 For clinical trials involving medicines it is a legal requirement that there should be insurance or indemnity to cover the 
liabilities of sponsors and investigators. 
20 For clinical trials involving medicines, the sponsor has to put and keep in place arrangements for the purpose of ensuring 
that the conditions and principles of Good Clinical Practice are satisfied or adhered to. 
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3.29 Universities and other employers of staff engaged in research are 
responsible for: 
 compliance with all current employment and health and safety 
legislation 
 demonstrating the existence of clear codes of practice in other areas 
for their staff and mechanisms to monitor and assess compliance 
 ensuring that the Chief Investigator and/or other research staff are 
aware of, understand and comply with this framework 
 discharging their agreed role in the management and monitoring of 
work undertaken by their organisation 
 demonstrating systems for continuous professional development of 
staff at all levels 
 having agreements and systems in place to identify, protect and 
exploit intellectual property 
 ensuring that they are able to compensate anyone harmed as a 
result of negligence on the part of their staff and, if they have agreed 
to do so, for non-negligent harm arising from the research 
 having in place systems to detect and address fraud, and other 
scientific or professional misconduct by their staff 
 having in place systems to process, address and learn lessons from 
any complaints brought against their employees 
 permitting and assisting in any investigation arising from complaints 
received in respect of actions taken by their employees 
 
RESPONSIBILITIES OF ORGANISATIONS PROVIDING CARE 
 
3.30 All organisations providing health and social care must be aware of all 
research being undertaken in their organisation, and any research 
involving participants, organs, tissue or data obtained through the 
organisation.  They should ensure that their service users and care 
professionals are provided with information about any research which 
may have a direct impact on their care, their experience of care, or their 
work in the organisation. 
 
3.31 Organisations providing care are also responsible for ensuring that any 
research involving their service users and carers or staff meet the 
standards set out in this framework, in particular that it has an identified 
research sponsor willing and able to discharge its responsibilities, and 
that clear and documented agreements are in place about the allocation 
of responsibilities between all parties involved.  Accountability for this 
lies with the Chief Executive but he or she may delegate responsibility 
for ensuring compliance to an appropriately qualified and senior 
member of staff, eg, the organisation’s director of research and 
development. The care provider remains responsible for the quality of 
all aspects of the care of their users, whether or not they are involved in 
research and by whoever that research may be conducted or funded. 
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3.32 Chief Executives of HSS bodies are accountable for quality under the 
statutory duty of quality as described in the clinical and social care 
governance guidance.  Researchers not employed by the HSS body 
who interact with individuals in a way which has direct bearing on the 
quality of their care should hold an honorary contract prior to 
commencing their research. 
 
3.33 A summary of the main responsibilities of organisations providing care 
are to: 
 retain responsibility for the quality of all aspects of participants’ care 
whether or not some aspects of care are part of a research study 
 be aware and maintain a record of all research work being 
undertaken through or within the organisation, including research 
undertaken by students as part of their training 
 ensure service users and carers are provided with information on 
research that may affect their care 
 be aware of any current legislation relating to research work and 
ensure that this is implemented effectively within the organisation 
 ensure that all research has been approved by an appropriate 
research ethics committee 
 ensure that all research has an identified sponsor who understands, 
accepts and is able to discharge their duties as set out in this 
framework 
 ensure a person authorised to do so has given written permission on 
behalf of the organisation providing care 
 ensure that written agreements are in place regarding 
responsibilities for all research involving an external partner, funder 
and/or sponsor, including agreement with a university or other 
employer in relation to student supervision 
 ensure that the necessary links with clinical and social care 
governance are made 
 ensure that non-HPSS employed researchers hold honorary 
contracts where appropriate and that there is clear accountability 
and understanding of who is responsible for what 
 put in place and maintain the necessary systems to identify and 
learn from errors and failures 
 put in place and maintain the necessary systems to process, 
address and learn lessons from complaints arising from any 
research work being undertaken through or within the organisation 
 ensure that significant lessons learnt from complaints and from 
internal enquiries are communicated to funders, sponsors and other 
partners 
 ensure that adverse incidents in the context of research are reported 
to the National Patient Safety Agency in line with the standard 
procedures of the organisation; or to the systems for adverse events 
reporting in social care 
 permit and assist with any monitoring, auditing or inspection required 
by relevant authorities 
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RESPONSIBILITIES OF CARE PROFESSIONALS 
 
3.34 Health and social care staff retain responsibility for the care of their 
service users, when they are participating in research. 
 
3.35 Before agreeing to their service users being approached, they must 
satisfy themselves that the research has been the subject of approval 
by appropriate scrutinising authorities within their organisation or 
agency, and that any research that relates directly to the care they 
provide complies with this framework. 
 
RESPONSIBILITIES RELATING TO RESEARCH ETHICS COMMITTEES 
 
3.36 No research study within the HPSS involving individuals, their organs, 
tissue or data may begin until it has a favourable opinion from an HPSS 
Research Ethics Committee (HPSS REC).  These committees are 
supported by the Office for Research Ethics Committees for Northern 
Ireland (ORECNI).  The HPSS RECs together with ORECNI constitute 
the Research Ethics Service for Northern Ireland and form part of the 
UK NHS Research Ethics Service. 
 
3.37 The United Kingdom Ethics Committees Authority (UKECA) is 
responsible for recognising ethics committees to review clinical trials 
under the Medicines for Human Use (Clinical Trials) Regulations 2004.  
The Human Tissue Act 2004 also requires ethical review by an 
appropriate body; normally, a research ethics committee.   
 
3.38 The Central Services Agency (CSA) is responsible for establishing and 
supporting HPSS RECs. These committees are established to review 
both health and social care research within the HPSS.  Those outside 
the HPSS may also seek the advice of these committees.   
 
3.39 Ethics committees are required to be independent when formulating 
advice on the ethics of the proposed research. Ethics review must be 
seen to be impartial. While they operate within a framework of 
standards and HPSS management, neither the DHSSPS nor any HSS 
body is entitled to interfere with the HPSS RECs’ decisions. The CSA 
as the HPSS RECs’ appointing authority must maintain systems to 
appoint members, to convene them, to seek recognition by UKECA, and 
to support them and monitor their performance. HPSS RECs are 
established to review both health and social care research in the HPSS.   
 
3.40 Ethics committees provide an independent opinion. The decision 
whether or not to give permission for research to proceed in a care 
organisation rests with that organisation. Subject to a favourable ethical 
opinion, health and social care organisations will not normally withhold 
permission unless there are local factors that would lead to an 
unacceptable impact on the quality of health or social care. 
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3.41 It is not for research ethics committees or reviewers to give legal advice, 
nor are they liable for any of their decisions in this respect. It is the 
researchers and the health or social care organisations21 who have the 
responsibility not to break the law. If a research ethics committee 
suspects that a research proposal might contravene the law, it is 
expected to advise both the Chief Investigator and the appropriate 
authority. Then the Chief Investigator and the organisation will need to 
seek legal advice. 
 
3.42 HPSS RECs should adhere to the provisions of the Governance 
Arrangements for Research Ethics Committees (GaFREC).  
Responsibility for assuring the scientific quality of a research study 
normally rests with the funder.  It is not the task of RECs to undertake 
additional scientific review, but to satisfy themselves that the review 
undertaken is adequate given the nature of the proposal. 
 
3.43 HPSS RECs require researchers working in the HPSS to keep them 
informed of the progress of a study. The committees are responsible for 
reviewing their advice on the ethical acceptability of a study in the light 
of such information. The Chief Investigator and his or her employer, the 
sponsor and the care organisation are responsible for ensuring that a 
study follows the agreed protocol, and for monitoring and reporting on 
its progress22. 
                                                 
21
 And the sponsor, for clinical trials involving medicines. 
22
 For clinical trials of medicines, sponsors have a legal duty to notify the ethics committee and the licensing authority of 
adverse events, a change to the design of the trial, and the conclusion of the trial. 
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BOX G: 
SPECIFIC RESPONSIBILITIES OF KEY PEOPLE INVOLVED IN RESEARCH 
 
WHO IS RESPONSIBLE FOR WHAT? – SOME QUESTIONS AND ANSWERS 
 
The Scenario: A university Senior Lecturer in General Practice is awarded a grant by the Medical 
Research Council (MRC) to conduct a trial on an existing drug but outside of its existing licence.  The 
grant is paid to the university.  The MRC was closely involved in the development of the trial design, 
and the study is based in the MRC’s General Practice Research Framework.  The manufacturer of the 
drug has agreed to provide it free.  The research is taking place in general practice.  It is agreed that 
the university should take on the responsibilities of sponsor.   
 
PATIENT 
 
Q: I did tell my GP that I might be interested in joining the study.  Does that commit me? 
A: Your GP has agreed to join this study and invite her patients to participate.  Whether or 
not you agree is entirely up to you. Unless you consent, you won’t be in the study.   
 
Q: How can I know the study is worthwhile? 
A: Through independent expert review (“peer review”), the MRC, as funder, assessed the 
clinical importance of the questions addressed by the study. It also assessed the 
design and oversight arrangements.  One of the HPSS Research Ethics Committees 
checked it is ethical. The MHRA authorised the use of the drug in this clinical trial.    
 
Q: How can I find out more about it? 
A: You can take away this patient information leaflet to study, and you can ask your GP or 
anyone on the research team for further details. 
 
Q: What if the drug involved does not agree with me? 
A: Your GP is responsible for your care.  She knows how we plan to monitor people who 
are in the trial.  We will tell her at once if we detect any problems, and you can 
approach her at any time. It is important for you to say if you have a bad reaction to the 
drug.   
 
GP 
 
Q: How do I know that this study is well designed? 
A: The university is sponsoring the study. The protocol names the sponsor’s contact 
point. The scientific design went through the MRC’s independent review system. It has 
ethical approval, and regulatory approval from the licensing authority. But you must 
decide whether you feel able to collaborate with it. 
 
Q: Who is responsible for the care of my patients if they agree to take part? 
A: You are.  The protocol explains the procedures the research team will follow and the 
circumstances in which they will alert you to anything they observe in your patients.  
You need to be satisfied with these arrangements.  Discuss them with the Chief 
Investigator if you are not. 
 
Q: I have agreed to join the study, but a number of my patients are having trouble understanding 
what they are being asked to take part in and why.  It’s taking up an enormous amount of 
time.  What should I do? 
A: You should talk to the Chief Investigator. A better understanding of the consent 
process could resolve these issues. Perhaps communication with your patients could 
be improved, for example by revising the patient information leaflet.  If the problem 
really can’t be solved, you can withdraw. 
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BOX G: (Continued) 
 
 
GP continued 
  
Q: Who is responsible for ensuring that the study is conducted according to the protocol and that 
the data are monitored to detect any possible problems? 
A: The Chief Investigator is responsible for ensuring that you and every other person 
involved in the study is well informed, and able to carry out their roles properly. This is 
a trial of a medicine, so there is a legal responsibility to follow the protocol. If you have 
any concerns about this, you should contact the Chief Investigator.  If you are not 
satisfied, you should inform the sponsor’s representative. 
 
Q: Who is responsible for the quality of the drugs? 
A: The pharmaceutical company supplying the drugs is responsible for their quality. 
Medicines have to be made in licensed facilities, and must be correctly labelled for 
trials.   
 
Q: One of my patients seems much worse since I entered him into the trial.  He is keen to 
continue, but I am concerned.  What should I do? 
A: You have a primary responsibility for the patient's care. You have a duty to put his 
safety before anything required by the research.  You should advise him to withdraw if 
you think that the trial drug caused his problems.  Explain to him that you will talk to 
the research team on his behalf.  It is very important that you notify the Chief 
Investigator of any concerns you have about treatment under the trial. In trials of 
medicines, it is a legal requirement to report harmful reactions to the MHRA so that 
everyone can learn from them.   
 
CHIEF INVESTIGATOR 
 
Q: How do I know when the trial is authorised? 
A: As it falls under the Medicines for Human Use (Clinical Trials) Regulations 2004, the 
trial has to be authorised by the MHRA. The MHRA notifies sponsors when trials are 
authorised. It is against the law for you to start recruiting until you know the MHRA has 
issued a Clinical Trial Authorisation. The sponsors’ representative will tell you when 
the drugs can be released for use in the trial. 
 
Q: What about ethical review? 
A: You have submitted the study to an ethics committee, recognised for this kind of 
study, using the electronic form available on Central Office for Research Ethics 
Committees (CORECs) website. You need a positive ethics committee opinion as well 
as a Clinical Trial Authorisation before you can start the trial.  (To come within HPSS 
indemnity, you also need permission from each HSS Trust before you seek to recruit 
anyone covered by that organisation’s duty of care). 
 
Q: To whom must I report an adverse event? 
A: For this trial, the sponsor has delegated to you the responsibility for recording and 
basis, so you have to follow the agreed process for recording adverse events, 
assessing seriousness, relatedness and expectedness, and reporting.  You must 
arrange to report any worrying reaction immediately to the patient’s GP.  Adverse drug 
reactions must also be reported to the Trial Steering Committee, the drug 
manufacturer, the MHRA, the ethics committee and the Data Monitoring Committee.  
Under the Clinical Trials Regulations, there is a legal obligation to report suspected 
unexpected serious adverse reactions (SUSARs) to the MHRA within a set period.  
 
reporting adverse events.  The MHRA will issue the Clinical Trial Authorisation on that 
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BOX G: (Continued) 
  
Q: I am concerned that the staff in the university labs are not following appropriate health and 
safety rules.  What do I do? 
A: You should raise this concern through the university’s local health and safety systems. 
 
Q: I am concerned not all the investigators will follow the protocol closely – what should I do? 
A: Inform the sponsor’s representative immediately and agree a course of action. 
 
Q: If my team need training, to whom should I talk? 
A: Their employer is normally responsible for their training. 
 
Q: To whom do I talk if I suspect that a university colleague is fabricating data? 
A: Your university, as your colleague’s employer, is responsible for investigating the 
suspected misconduct.  Others such as the General Medical Council may also be 
responsible for looking into your suspicions if they appear to involve professional 
misconduct.  If you suspect someone employed by another organisation, raise your 
concerns with your employer, who as sponsor will contact your colleague’s employer.  
In any case, record the evidence carefully so that there can be a proper investigation. 
 
Q: I have new information that makes me think we could improve the design of this study.  What 
do I do? 
A: Discuss it with the Trial Steering Committee.   If they agree, you need to draw up a 
revised protocol, and submit this to the sponsor.  As funder, the MRC should also be 
informed.  They may decide that the revised protocol should go through a further 
process of scientific review.  The amended protocol must also be submitted to both the 
MHRA and the relevant ethics committee.  You must not implement substantial 
changes to the protocol without formal agreement from those who gave permission for 
the study (particularly the MHRA and the ethics committee).  When an amendment is 
authorised, you need to tell all investigators to follow the new protocol from a specified 
time. 
 
Q: I think I have generated some important intellectual property.  What should I do? 
A: Your employer as sponsor will have a policy on IP that complies with the terms of 
funding. You should refer to and comply with this policy, which is likely to be part of 
your conditions of employment. Your employer may have an IP unit that can help you 
follow the right procedures. 
 
Q: What if the MHRA does a Good Clinical Practice inspection? 
A: You must cooperate. The inspectors have legal powers to ask for documents and take 
enforcement action. Generally, they look for evidence of good systems that are 
proportionate to the risks involved. The MHRA will point out any improvements needed 
for trial sites to comply with the law. They seek a prosecution only if it would be in the 
public interest because of very serious or persistent failure. 
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Section 4 Achieving Governance 
 
DELIVERY SYSTEMS 
 
4.1 Organisations undertaking, sponsoring, funding or hosting health and 
social care research must have systems in place to ensure that they 
and their staff understand and follow the standards and good practice 
set out in this framework.  In Northern Ireland the R&D Office will, on 
behalf of the Department, lead in taking forward the research 
governance agenda.  The R&D Office working with partner 
organisations will: 
 provide a regional perspective on the development and maintenance 
of proper research governance 
 lead on the development of appropriate research governance 
policies for the HPSS, providing a comprehensive underpinning 
framework and offering a comprehensive set of research governance 
policies for adoption by individual HSS bodies 
 unify, co-ordinate and streamline research governance procedures in 
the areas of regulation, approvals, management and reporting in a 
manner that minimises bureaucracy and maximises effectiveness 
 develop and maintain common systems which support a combination 
of centralised and decentralised functions designed to address the 
needs of all those involved in HPSS R&D 
 seek to ensure that research governance is delivered in a manner 
that: facilitates R&D integration with patient care; removes 
unnecessary barriers to research in the HPSS; helps service users 
participate in and benefit from HPSS R&D; and protects the rights 
and safety of all those involved in HPSS R&D 
 
4.2 Research funders should have systems in place, or have access to 
systems to undertake expert independent review – appropriate to the 
scale and complexity of research proposals – to ensure the scientific 
and ethical standing of any proposed research study, its strategic 
relevance and value for money.   
 
4.3 Research sponsors must ensure that systems are in place – managed 
either by themselves or by one of the organisations involved in the 
research, such as the host university, a funding body, or care provider – 
to ensure that all research they sponsor is conducted according to the 
agreed protocol, to monitor its general progress and to discuss and 
agree modifications to the protocol if the need arises. 
 
4.4 All health and social care providers must have systems in place to 
ensure that they are aware of, and have given permission for, all 
research being conducted in or through their organisation, whether or 
not it is externally funded.  Care providers should only give permission 
for research which has a sponsor.  Care providers may only themselves 
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take on the role of sponsor if they have systems in place to discharge 
those responsibilities.  It is acceptable for an individual employee to be 
a sponsor, but only with the written permission of that person’s 
employer23.  Whoever acts as sponsor, care providers must satisfy 
themselves that systems are in place, either in their own organisation or 
elsewhere, to ensure that all research conducted in or through their 
organisation conforms to appropriate scientific and ethical standards, 
and offers value for public money. 
 
4.5 Nothing in this research governance framework is intended to transfer 
the legal duties of health and social care organisations to sponsors or to 
others. Irrespective of whoever takes on sponsorship, if a study affects 
an HSS body’s duty of care, it remains that organisation’s responsibility 
to satisfy itself that there are systems in place to ensure a research 
study is conducted to appropriate scientific and ethical standards. 
 
4.6 HPSS RECs and expert reviewers should have systems to identify, 
record and address conflicts of interest that may compromise, or appear 
to compromise, the independence of their advice. They must also have 
systems to record their decisions and the reasons for them, and to 
record operational details of their meetings and handling of applications. 
In 2005, the National Patient Safety Agency became responsible for the 
Central Office for Research Ethics Committees (COREC), providing 
advice, assistance and national systems to support the work of research 
ethics committees.  In Northern Ireland, HPSS RECs are supported by 
ORECNI which is closely linked to COREC.    
 
4.7 Delivery systems should be designed to detect failures to adhere to 
requirements, regardless of whether such failures arise by intent or 
oversight.  Such systems should involve routine and random monitoring 
and audit as appropriate.  Additionally, delivery systems should require, 
facilitate and support reporting of critical incidents, near misses, 
systems failures and misconduct either by self-reporting or whistle-
blowing. 
 
4.8 Research governance depends critically on research workers and 
research managers understanding their responsibilities and having the 
skills needed to discharge them.  The Department through the R&D 
Office will work with other research funders; the universities and HSS 
bodies involved in research to promote the awareness of research 
governance. 
 
                                                 
23 For clinical trials of medicines, it is within the law for an individual to be the sponsor.  Employers should ensure that, if their 
employees take on sponsorship, there is a system to record whether the employee has permission to do so as a private 
individual or is authorised to do so on behalf of the employer.  Health and social care organisations should authorise their 
employees to take on sponsorship, only if there are arrangements to perform the functions in the Medicines for Human Use 
(Clinical Trials) Regulations 2004. 
43 
MONITORING, INSPECTION AND FAILURES   
 
4.9 Organisations and individuals must be able to demonstrate adherence 
to this framework to reassure service users and care professionals of 
the quality of their services and to assure their reputation in high quality 
research and care. 
 
4.10 There are already incentives to adhere to many of the principles and 
standards set out in the framework.  These include the law, the duties of 
care and the duty of quality in the HPSS and the high professional and 
ethical standards upheld by the majority of care professionals and 
researchers.  Mechanisms, which monitor the quality of clinical and 
social care such as audit, risk management and staff appraisal can 
assist in the monitoring of research governance at a local level.  
Nevertheless, a coherent system is needed to monitor performance 
against this research governance framework, to identify best practice 
and shortfalls, to enhance public confidence and help to prevent 
adverse events.  Where minimum acceptable standards are not met, 
sanctions are needed. 
 
4.11 Arrangements will be established to work with and through structures 
that already exist or are being developed in HSS bodies, government 
departments, research councils, universities and charities to promote 
and monitor quality. These arrangements will monitor the extent to 
which the standards set out in this framework are being followed by: 
 organisations undertaking sponsorship responsibilities 
 HSS bodies participating in research 
 universities and other organisations employing researchers 
 other organisations on which this framework depends 
 
4.12 Research governance is one of a set of quality systems for health and 
social care. Reporting, inspection and review supports organisations’ 
systems for meeting standards and managing risk. The National Patient 
Safety Agency maintains a national system for reporting adverse events 
in the NHS/HPSS. There are systems for reporting adverse events in 
social care. Clinical trials of medicines require authorisation by the 
Medicines and Healthcare products Regulatory Agency. The Agency 
operates a system of Good Clinical Practice and Good Manufacturing 
Practice inspections. They can involve trial sites, units manufacturing 
investigational medicinal products, and sponsors. Similar arrangements 
apply to medical devices.   
 
4.13 The Department will introduce research governance as one of the core 
standards all organisations should achieve in delivering HPSS care. 
HSS organisations which either lead or participate in research should 
have systems to ensure that the principles and requirements of this 
research governance framework are consistently applied.  
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4.14 There is public and professional concern about research misconduct 
and fraud, though its extent is unknown.  Monitoring of research 
governance will check that appropriate systems are in place to detect 
and investigate possible fraud and to take appropriate action if fraud is 
found.  In addition, HSS bodies should themselves ensure that 
universities and any other organisations with whom they develop 
partnerships have appropriate systems for detecting, investigating and 
addressing fraud by their employees. 
 
4.15 Failures on the part of staff in the Department or the HPSS to comply 
with the requirements of this framework, or to meet their responsibilities 
relating to this framework, will be addressed through normal 
management channels and disciplinary procedures.  The Department 
will look to those with responsibilities within HSS bodies or in other 
organisations to address any shortcomings which exist.  Departmental 
and HPSS R&D funds will only be allocated to those competent to 
manage the work they support.  It is the responsibility of other 
organisations to have appropriate systems in place to address failures 
by their staff.  Monitoring arrangements will verify that these are in 
place.  Where such a failure occurs, University employees with HPSS 
honorary contracts may have these withdrawn, subject to a joint 
HPSS/university investigation. 
 
4.16 In the case of misconduct, some professional groups will be subject to 
disciplinary action by their professional bodies.  Doctors are responsible 
to the General Medical Council for their professional conduct as 
researchers as well as clinicians.  Similarly, dentists are responsible to 
the General Dental Council, nurses, health visitors and midwives are 
responsible to the Nursing and Midwifery Council and Allied Health 
Professionals are responsible to the Health Professions Council.  
Misconduct by social care professionals will be the responsibility of the 
Northern Ireland Social Care Council. 
 
4.17 Professional judgement is involved in the interpretation of this guidance. 
Quality in research depends on those responsible being appropriately 
qualified, with the skills and experience to use their professional 
judgement effectively in the delivery of dependable research. 
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This document builds on a range of earlier published work and draws 
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